Dedicated to the cherished memory of Alberto Gulino. REFERENCES 1 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233. 2 Giambra V, Jenkins CR, Wang H, Lam SH, Shevchuk OO, Nemirovsky O et al. NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-theta and reactive oxygen species. Nat Med 2012; 18: 1693-1698. 3 Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia.
In pediatric patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), approximately three-quarters harbor wellcharacterized, clinically relevant chromosomal alterations, including hyperdiploidy, hypodiploidy, t(12;21) ETV6/RUNX1, t(1;19) E2A/ PBX1, t(9;22) BCR/ABL1 and the rearrangement of MLL at 11q23, and they can facilitate diagnosis, risk stratification and targeted therapy. 1, 2 In the remaining patients, however, major pathogenic or driver gene abnormalities and their association with the clinical outcome have yet to be fully clarified. As recent advanced genomic studies using next-generation sequencing have identified a number of novel fusion genes and stratified a high-risk subtype in BCP-ALL, [3] [4] [5] unknown genetic alterations that constitute characteristic subgroups may still exist in the remaining patients. We therefore intended to investigate unknown fusion genes in BCP-ALL by using next-generation sequencing.
As a consequence of whole transcriptome sequencing performed on complementary DNA from 55 selected samples of pediatric BCP-ALL patients without conventional genetic abnormalities (Supplementary Information), an EP300-ZNF384 fusion gene was identified in two patients (Cases 1 and 2) as a repeatable and plausible candidate fusion gene ( Figure 1a ). The 372-bp fragment of the EP300-ZNF384 fusion cDNA was amplified by RT-PCR using a pair of specific primers, and Sanger sequencing of the PCR products revealed a sequence of the products identical to that obtained by whole transcriptome sequencing (Supplementary Figure 1 ). The presence of EP300-ZNF384 fusion in Case 1 was further confirmed by FISH using a combination of appropriate probes for EP300 and ZNF384, respectively ( Figure 1b ). We screened a further 346 of pediatric ALL cases by RT-PCR, and identified 4 additional patients with EP300-ZNF384 fusion (Cases 3-6, Supplementary Figure 1 ). All six patients were BCP-ALL without conventional cytogenetic abnormalities. Our RNA samples Accepted article preview online 6 May 2015; advance online publication, 22 May 2015 used in this study were obtained from the patients consisted of an uncontinuous series of 68 BCP-ALL without conventional cytogenetic abnormalities and a continuous series of 333 ALL patients, including 291 BCP-ALL patients (133 patients without conventional cytogenetic abnormalities, Supplementary Information). As three out of six cases of EP300-ZNF384+ BCP-ALL (Cases 2-4) belong to later group, the frequency of EP300-ZNF384 expression in BCP-ALL was estimated as 1.03% (0.90% in total ALL, 2.26% in BCP-ALL without conventional cytogenetic abnormalities) in our cohort.
EP300 encodes the E1A-binding protein p300 (EP300), a transcriptional co-activator closely related to CREB-binding protein (CBP) and with the ability to interact with a wide spectrum of transcription factors and histone acetyltransferase activity. 6 On the other hand, the zinc-finger protein 384 (ZNF384) gene encodes a transcription factor that regulates promoters of the extracellular
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Zinc finger, Figure 1 . Detection of the EP300-ZNF384 fusion gene. (a) Two split sequences of EP300-ZNF384 obtained from two individual patients by whole transcriptome sequencing were aligned. Complementary DNA showing fusion of the intron following EP300 exon 6 and the intron preceding the first coding exon (exon 3) of ZNF384. Amino-acid sequences of the predicted EP300-ZNF384 fusion protein are presented. Arrows indicate the fusion points. The box indicates the initiation codon of ZNF384. #, inserted amino acids originating from the 5′ untranslated 5-bp sequence of ZNF384. The predicted EP300-ZNF384 protein is schematically indicated. NRID, nuclear receptor interaction domain; TAZ1, transcriptional adaptor zinc-finger domain 1 (also known as the cysteine-histidine-rich (CH) region (CH1)); KIX, kinase-inducible domain of CREB-interacting domain; Bd, bromodomain; RING, 'really interesting new gene' domain; PHD, plant homeodomain; HAT, histone acetyltransferase domain; ZZ, ZZ-type zinc-finger domain; TAZ2, transcriptional-adaptor zinc-finger domain 2 (the RING-PHD segment is also known as the CH2 region, and the ZZ-TAZ2 domain as the CH3 region); IBiD, IRF3-binding domain; LZ, leucine-rich domain; SR, serine-rich domain; PR, proline-rich domain; NLS, nuclear localization signal; ZFs, Kruppel-type C2H2 zinc-finger domains; QA, Gln-Ala repeat. (b) The results of FISH using the EP300 probe (green) and ZNF384 probe (red) are indicated. The fusion signals are indicated by yellow arrowheads. matrix genes. 7 Chromosomal translocations involving EP300 fused to either Monocytic leukemia zinc-finger protein (MOZ) or Mixed lineage leukemia (MLL) genes are associated with acute myeloid leukemia. 8, 9 ZNF384 is known to be involved in ALL through fusion with the TET family gene, such as the Ewing sarcoma breakpoint region 1 (EWSR1) gene, TATA box binding protein-associated factor (TAF15) and transcription factor 3 (TCF3 or E2A). 10, 11 Although the mutations of both EP300 and ZNF384 are known to be involved in the development of leukemia, this is the first report on the EP300-ZNF384 fusion gene.
The resulting sequence of the EP300-ZNF384 fusion gene (Figure 1a ) revealed that exon 6 of EP300 was fused to exon 3 (the first coding exon) of ZNF384. The fusion point of ZNF384 is the same as those of previously reported ZNF384-related fusion genes between TAF15 and E2A genes. 10, 11 The 5-bp sequence upstream of the initiation codon in ZNF384 is included, while the EP300-ZNF384 fusion transcripts were predicted to encode a fusion protein with in-frame joining between the N-terminal portion of EP300 and the entire ZNF384 protein. A schematic representation of the EP300-ZNF384 fusion protein predicted to encode a 110-kDa protein with 1027 amino acids 10,12 is shown in Figure 1a . The EP300-ZNF384 fusion protein retains the transcriptional adapter zinc-finger 1 (TAZ1) domain in the cysteine-histidine-rich region 1 (CH1) of EP300, but it lacks the other domains such as the histone acetyltransferase (HAT) domain to be included in EP300. On the other hand, the complete ZNF384 protein is retained in the EP300-ZNF384 fusion.
The clinical findings of EP300-ZNF384 fusion-positive patients are summarized in Table 1 . The patients were aged between 7 and 17 years (mean: 11.5 ± 3.8), comprised four males and two females, and were all classified into an intermediate risk group at the initial diagnosis based on an advanced age. 13 Their initial white blood cell count ranged from 2300 to 17 330 (mean: 8730 ± 5849). All patients showed a good response to steroid monotherapy, using the cutoff of 1000/μl for the blast count in peripheral blood on day 8. 13 All six patients achieved complete hematological remission after induction therapy. Four patients (Cases 2, 3, 4 and 6) completed the entire protocol and maintained complete remission for 4-10 years. One patient (Case 5) received maintenance therapy and was in complete remission for 2 years and 1 month. The remaining patient (Case 1) also completed the initial therapy, but he relapsed in the off-therapy period, and he is now in his fourth complete remission after a second bone marrow transplantation.
Importantly, the predicted chromosomal translocation t(12;22) (p13;q13) was not detected in all six cases by conventional G-banding, and five patients (Cases 2-6) showed a normal karyotype on cytogenetic analysis. The remaining patient (Case 1), who had relapsed three times, consistently showed 46,XY, t (9;10)(p13;p13) from the initial diagnosis through to the third relapse, whereas corresponding gene fusion was not identified by whole transcriptome sequencing. As FISH confirmed the presence of EP300-ZNF384 translocation in Case 1 and 954 among 1000 cells showed positive fusion signals, it is suggested that translocation leading to EP300-ZNF384 is difficult to detect with conventional G-banding.
All six EP300-ZNF384+ cases revealed dull or negative expression of CD10 based on immunophenotypic examination ( Supplementary Figure 2 , Supplementary Table) . They also exhibited negative expression of cytoplasmic μ chain. In addition, each case aberrantly expressed one or more myeloid antigen(s), including CD13 and CD33. Therefore, most BCP-ALL patients carrying the EP300-ZNF384 fusion gene may be predictable based on their characteristic immunophenotype.
The EP300-ZNF384 fusion and conventional cytogenetic abnormalities are mutually exclusive. FISH analysis revealed that a vast majority of leukemic blasts express the fusion. The above data suggest the involvement of this fusion gene in the development of BCP-ALL, whereas the functional role of this fusion gene is not yet known. As we present in Figure 1a , the EP300-ZNF384 fusion protein is predicted to lack the HAT domain of EP300. It has been suggested that the deregulation of acetylation could lead to a disruption in the balance between proliferation and differentiation during hematopoiesis and in vivo structure-function analysis of EP300 by others demonstrated that the loss of HAT activity results in an increase in the numbers and proliferative potential of hematopoietic progenitors and stem cells. 14 Furthermore, it has been reported that some B-cell lymphoma harbor frequent structural alterations inactivating CREBBP or EP300 as a major pathogenetic mechanism, reading to specific defects in acetylation-mediated inactivation of the BCL6 oncoprotein and activation of the p53 tumor suppressor. 15 Therefore, the N-terminal portion of EP300 without the HAT domains in the EP300-ZNF384 fusion may be involved in the development of ALL by deregulating acetylation, but further functional evaluation is necessary.
In contrast, the complete ZNF384 sequence is retained in the EP300-ZNF384 fusion, being the same as in cases of other ZNF384related recurrent fusions observed in acute leukemia. 10, 11 Both EWSR1-ZNF384 and TAF15-ZNF384 have transforming properties in NIH3T3 cells, but do not alter expressions of known ZNF384 target genes. 10 The functions of the ZNF384 gene in these fusion genes remain unclear and should also be investigated in the future.
In conclusion, we identified a novel recurrent fusion gene between the EP300 and ZNF384 genes in children with BCP-ALL. Further studies involving a large series of patients should be conducted to elucidate the oncogenic properties of EP300-ZNF384 and confirm the clinical and biological features of patients with BCP-ALL harboring the EP300-ZNF384 fusion gene.
